abstract |
The present invention relates to a semi-lived respiratory syncytial virus (RSV) vaccine comprising a genomic replication deficient Sendai virus (SeV) vector expressing a chimeric RSV / SeV F protein. Furthermore, the present invention relates to a method for producing the genome replication-deficient SeV vector of the present invention, and its use in the treatment of RSV infection and RSV infection-related diseases. [Selection] Figure 1 |